VYLUMA ANNOUNCES POSITIVE RESULTS FROM SECOND STAGE OF PHASE III CHAMP STUDY OF NVK002 FOR THE TREATMENT OF MYOPIA IN CHILDREN Read More
VYLUMA ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR NVK002, ITS NOVEL INVESTIGATIONAL TREATMENT FOR PEDIATRIC MYOPIA Read More
VYLUMA ANNOUNCES POSITIVE RESULTS FROM PHASE 3 CHAMP STUDY OF NVK002 FOR TREATMENT OF MYOPIA PROGRESSION IN CHILDREN Read More
VYLUMA COMPLETES LAST PATIENT VISIT FOR PRIMARY ANALYSIS OF PIVOTAL PHASE III CHAMP STUDY EVALUATING NVK002 FOR THE TREATMENT OF MYOPIA PROGRESSION IN CHILDREN Read More
Vyluma and Laboratoires Théa Enter into Licensing Agreement for the Registration and Commercialization of NVK002 in Canada, Mexico, and Select South American Countries Read More
Nevakar Announces Closing of $12 Million Convertible Note and Extension of Interest- Only Period with Oxford Finance Read More
VYLUMA AND MYMYOPIA.COM SUPPORT 2021 WORLD SIGHT DAY TO RAISE AWARENESS OF VISION DISORDERS Read More
